Wistar

Wistar Research Identifies Mechanisms for Selective Multiple Sclerosis Treatment Strategy

Retrieved on: 
Dienstag, Mai 28, 2024
Wistar, EBV, PML, Bangladesh Technical Education Board, Phenotype, Nature Microbiology, Nervous system, Patient, Data collection, Wistar Institute, TAF, Sclerosis, Immune system, Travel, FOXP1, Disease, DSM-IV codes, Multiple sclerosis, Epstein–Barr virus infection, SLCL, Liebermann, Neuron, Collaborative writing, Gene, Immortalised cell line, Cell, Manuscript, IL-6, Brain, Inflammation, R01, Vaccine

Though researchers know that EBV can contribute to the development of MS, the exact mechanisms by which it does so aren’t completely understood.

Key Points: 
  • Though researchers know that EBV can contribute to the development of MS, the exact mechanisms by which it does so aren’t completely understood.
  • As a whole, the group’s findings suggested a mechanism of lytic EBV in MS that promoted inflammation and disease.
  • TAF also significantly reduced the expression of inflammatory cytokines like IL-6 in the SLCLs from the patients with active MS.
  • The funders had no role in study design; data collection and analysis; decision to publish; or preparation of the manuscript.

Wistar Scientists Discover New Immunosuppressive Mechanism in Brain Cancer

Retrieved on: 
Freitag, Mai 3, 2024
Cell, National Cancer Institute, Macrophage, Sapienza University of Rome, Genome, Glucose, Wistar Institute, Gene, Brain, Tumor microenvironment, Wistar, Metabolomics, Neuroscience, Immunity, Ben, Medical research, Microglia, Research, Proteomics, Immunology, Histone, Malignancy, Gene expression, Neoplasm, Aurelia, Cancer, Collaborative writing, DSM-IV codes, Prognosis, Immunosuppression, Immunotherapy, Duke School, Disease, GLUT1, Patient, Metabolism, Immune system, Angelica, Vaccine

The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.

Key Points: 
  • The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.
  • Indeed, monocyte-derived macrophages, but not microglia, blocked the activity of T cells (immune cells that destroy tumor cells), in preclinical models and patients.
  • Glioblastoma is inherently dangerous due to its location in the brain and its immunosuppressive tumor microenvironment, which renders glioblastoma resistant to promising immunotherapies.
  • Note: The work detailed in this publication was initiated at The H. Lee Moffitt Cancer Center during Dr. Veglia’s time there and continued at Wistar.

Wistar Scientists Discover Link Between Leaky Gut and Accelerated Biological Aging

Retrieved on: 
Freitag, Februar 23, 2024
Methylation, Dysbiosis, Culture, Penn Center, Health, Bacteria, University, Subtypes of HIV, Life Length, Wistar Institute, Bangladesh Technical Education Board, Ileum, Infection, NIH, AIDS, Glass, Metabolomics, Nucleotide, DSM-IV codes, Biomedical Research, HIV/AIDS research, Wistar, University of Pittsburgh, DNA, Immune system, National Institutes of Health, Leiden University Medical Center, Weill Cornell Medicine, Hannum, Research, Inflammation, Blood, Ageing, Cancer, Cell biology, Microbiome, Rush University, HIV, DNA methylation, Vaccine

Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.

Key Points: 
  • Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.
  • A prime suspect in this aging puzzle is the gut microbiome and its potential leakage into the bloodstream.
  • The Abdel-Mohsen lab investigates how gut leakage can impact the immune system and lead to chronic inflammation, which may accelerate aging.
  • Their analysis revealed a significant connection between disrupted gut microbiomes, increased intestinal permeability (leaky gut), and faster biological aging.

Wistar Scientists Engineer New NK cell Engaging Immunotherapy Approaches to Target and potentially Treat recalcitrant Ovarian Cancer

Retrieved on: 
Mittwoch, November 1, 2023
Ovarian cancer, Neoplasm, Survival, VIC, Wistar Institute, Biomedical Research, Hook effect, Siglec, Sial, Infection, Cell biology, BRCA1, FSHR, PD-1, Nature, BRCA, Research, Follicle-stimulating hormone, University of Pennsylvania, Observation, CPI, BRCA2, CDC, Vaccine, Immune system, NK, Risk, Antibody, Cancer, Cancer research, Wistar, Natural killer T cell, Perelman School of Medicine at the University of Pennsylvania, University, OC, NIH, Culture, Woman, Patient, Toxicity, PARP, Pharmaceutical industry, Fine chemical, Monoclonal antibody, Science Advances

Ovarian cancer demonstrates a low response rate to standard-of-care treatments like chemotherapies, PARP inhibitors and the widely used checkpoint inhibitor, PD-1.

Key Points: 
  • Ovarian cancer demonstrates a low response rate to standard-of-care treatments like chemotherapies, PARP inhibitors and the widely used checkpoint inhibitor, PD-1.
  • In the small proportion of ovarian cancer patients that do respond to these treatments, resistance becomes problematic over time — resulting in tumor escape and cancer progression.
  • NK cells have been recently described to express Siglec-7, so the team tested two new strategies to engage and activate NK cells against ovarian cancer through Siglec-7.
  • Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology.

Wistar Researchers Discover Possible New Treatment for Triple-Negative Breast Cancer

Retrieved on: 
Dienstag, September 19, 2023
TNBC, CRISPR, PBCC, Cell biology, University, Molecule, Nature Cancer, ACSS2, Culture, Genomics, DP2, HER2, Wistar, Breast, Infection, HIC, Cancer, Biomedical Research, Immunity, Jim Valvano, Research, Zhug, Bangladesh Technical Education Board, Ellen, National Cancer Institute, Triple-negative breast cancer, Patient, Metabolism, Wistar Institute, Immune system, University of Bologna, NCI, P30, NIH, Breast cancer, Vaccine

Schug’s paper — titled, “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” — demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.

Key Points: 
  • Schug’s paper — titled, “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” — demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.
  • Triple-negative breast cancer, or TNBC, affects 10-15% of patients with breast cancer in the US.
  • The absence of any of these receptors — receptors that, when present in other forms of breast cancer, can be effectively targeted during treatment — makes treating TNBC quite difficult, and patients with TNBC have limited treatment options.
  • TNBC’s notorious aggression makes the technical challenge of finding a reliably effective treatment target all the more serious: compared to other breast cancers, TNBC grows faster and resists treatment more stubbornly.

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
Dienstag, August 22, 2023
DNA, Cell biology, Methylation, MBio, Hereditary diffuse gastric cancer, Collaborative writing, Cone Health Women's Hospital, Culture, Wistar, Infection, Cancer, Biomedical Research, Epstein–Barr virus, Research, Gene expression, Cell, T32, National Institutes of Health, Bangladesh Technical Education Board, Harvard Medical School, Ellen, Cytosine, Coriell Institute for Medical Research, Genome, Epigenome, Wistar Institute, Tempera, Hospital, DNA methylation, Stomach, P30, NIH, Medical research, EBV, Vaccine, Pharmaceutical industry, Decitabine, Brigham

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
Dienstag, August 22, 2023
DNA, Cell biology, Methylation, MBio, Hereditary diffuse gastric cancer, Collaborative writing, Cone Health Women's Hospital, Culture, Wistar, Infection, Cancer, Biomedical Research, Epstein–Barr virus, Research, Gene expression, Cell, T32, National Institutes of Health, Bangladesh Technical Education Board, Harvard Medical School, Ellen, Cytosine, Coriell Institute for Medical Research, Genome, Epigenome, Wistar Institute, Tempera, Hospital, DNA methylation, Stomach, P30, NIH, Medical research, EBV, Vaccine, Pharmaceutical industry, Decitabine, Brigham

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.

Award-Winning Biotech Training Program Connects Philadelphians with Quality Jobs in the Region’s Rapidly Growing Life Sciences Sector

Retrieved on: 
Montag, August 14, 2023
Molecular biology, Philadelphia Naval Shipyard, Member of Congress, Associate, American Chamber of Commerce in the People's Republic of China, Chamber, Patient, Wistar Institute, CRA, Cell, Commercial, Certified Research Administrator, Commerce, Interview, CHOP, Philly Shipyard, PIDC, Research, Literacy, Organization, Caribbean Programme for Economic Competitiveness, Good, GED, Growth, University City Science Center, Learning, Employment, TIL, Curriculum, Wistar, Cancer, CCP, Workforce, Operation, Partnership, Education, Doctor of Philosophy, Navy Yard, Woman, Student, City, Shipyard, Navy, Reading, Ecosystem, Pharmaceutical industry, Tutoring, Management, Nursing, Shipbuilding, Creative industries, Greater, Iovance Biotherapeutics

In a field that often requires PhDs or master’s degrees for most roles, the program – “Biomedical Technician Training Program: Aseptic Manufacturing” – creates opportunities for Philadelphians with at least a high school equivalency.

Key Points: 
  • In a field that often requires PhDs or master’s degrees for most roles, the program – “Biomedical Technician Training Program: Aseptic Manufacturing” – creates opportunities for Philadelphians with at least a high school equivalency.
  • The initiative is one way the region is working together to meet the talent needs in its rapidly growing cell and gene therapy sector.
  • The program connects Philadelphians to robust biomedical training at The Wistar Institute and offers program graduates a direct path to full-time, career-ladder employment as Associate Aseptic Manufacturing Technicians at Iovance.
  • Calibrated specifically to meet the needs of a burgeoning sector, the Biomedical Technician Training Program is designed for replication across industry employers.

New Community Partnership Model Boosts Participant Inclusion into HIV Cure-Directed Research

Retrieved on: 
Dienstag, August 8, 2023
Partnership, Cell biology, University, CAB, DATE, HIV, National Institute of Mental Health, Culture, HIV-1, Policy, Infection, Cancer, Stroke, Mental health, Biomedical Research, Community advisory board, University of California, San Diego, Research, History, CEG, Person, The Philadelphia Foundation, Organization, National Institute of Neurological Disorders and Stroke, DSM-IV codes, Community, Trust, AIDS, Patient, Wistar Institute, National Institute on Drug Abuse, United States Military HIV Research Program, Montaner, Team, National Institute of Allergy and Infectious Diseases, Pharmaceutical industry, Medical device, Engagement, Wistar

Now, researchers from The Wistar Institute are sharing how a more inclusive model for community engagement can lead to deeper insights and greater community participation in HIV research.

Key Points: 
  • Now, researchers from The Wistar Institute are sharing how a more inclusive model for community engagement can lead to deeper insights and greater community participation in HIV research.
  • The community engagement group, or CEG model, is composed of a three-part structure with a Community Advisory Board (CAB), Community nonprofit organization, and researchers.
  • , vice president for scientific operations, Herbert Kean, M.D., Family Professor , director, HIV-1 Immunopathogenesis Laboratory, and leader, HIV Research Program , Vaccine & Immunotherapy Center at The Wistar Institute.
  • Publication information: “Community engagement group model in basic and biomedical research: lessons learned from the BEAT-HIV Delaney Collaboratory towards an HIV-1 cure,” Research Involvement and Engagement (DATE).

Wistar-Led Team Awarded More Than $12 Million Grant from the NCI to Investigate Link Between Epstein-Barr Virus and Carcinomas

Retrieved on: 
Mittwoch, Juli 26, 2023
Infection, Life, Collaborative writing, Cancer, Harvard University, Epithelium, P01, Epstein–Barr virus, Research, Ellen, Malignancy, National Cancer Institute, Translational medicine, Gene expression, Wistar Institute, Metabolomics, Lymphoma, Drug discovery, Tempera, Chemical biology, NCI, Carcinoma, Virus, EBV, Pharmaceutical industry, Wistar

The multidisciplinary team led by Wistar scientists is exploring the role of Epstein-Barr Virus in epithelial cancers.

Key Points: 
  • The multidisciplinary team led by Wistar scientists is exploring the role of Epstein-Barr Virus in epithelial cancers.
  • The new research will focus on basic questions about how EBV infection of normal epithelial cells transforms them into cancer-cells.
  • It’s the first time researchers from this variety of disciplines have combined their efforts to focus entirely on the EBV-epithelial cancer link.
  • Tempera said the group’s integrated approach sets it apart.“Our project will study both metabolic and epigenetic vulnerabilities simultaneously,” he said.